Association of PTPN11 clonal rank with clinical outcome. Kaplan-Meier analysis showing the probability of (A) OS, RFS, and EFS for AML patients without (wt; black) or with PTPN11 mutation in subclonal (PTPN11^SUB; blue) or dominant (PTPN11^DOM; red) configuration, as well as OS in ELN-2017 favorable (D), intermediate (E), and adverse (F) risk groups. Numbers at risk are presented below each figure.